Nipocalimab in Moderate to Severe Sjogren's Disease
Status:
RECRUITING
Trial end date:
2030-04-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).